secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001193125-21-323850
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic and Ginkgo announce clinical candidate SYNB1353 for homocystinuria; IND filing expected 2022
--------------------------------------------------------------------------------

- SYNB1353 is an investigational Synthetic Biotic medicine for homocystinuria (HCU), developed using Synlogic's platform and Ginkgo's codebase.
- First candidate from Synlogic-Ginkgo collaboration to enter IND-enabling studies.
- Synlogic expects to file an IND with FDA and begin clinical development in 2022.
- Preclinical data to be presented at International Congress of Inborn Errors of Metabolism 2021 (Nov 21-23).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000119312521323850/0001193125-21-323850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000119312521323850/d232569d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-323850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer